WallStreetZenWallStreetZen

NASDAQ: REVB
Revelation Biosciences Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Revelation Biosciences earnings were -$19.2M for the trailing 12 months ending Jun 30, 2026, with -97.1% growth year over year. The latest REVB earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$3.3M, down 61.8% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, REVB reported annual earnings of -$14.9M, with -1.2% growth. The next REVB earnings date is Nov 5, 2026.

REVB past earnings growth

How has REVB's earnings growth performed historically?

Company
-97.08%
Industry
17.49%
Market
92.16%
REVB's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
REVB's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance

REVB earnings history

Current Revenue
$0.0
Current Earnings
-$19.2M
Current Profit Margin
0%

REVB Return on Equity

Current Company
-179%
Current Industry
-13.6%
Current Market
31%
REVB's Return on Equity (-179%)... subscribe to Premium to read more.
High Return on Equity Performance

REVB Return on Assets

Current Company
-147.8%
Current Industry
-10.2%
REVB is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when REVB announces earnings.

REVB Return on Capital Employed

Current Company
-101.25%
Current Industry
-6.7%
REVB's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

REVB vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
REVB-$10.59M-$19.20M-93.90%$4.37
TCRT-$3.99M-$4.01MN/A-$1.91
PPBT$25.75M$24.49MN/A-$48.36
EOCNN/A-$11.34MN/A-$15.12
CVKD-$11.54M-$11.54MN/A-$4.90
View Top Biotech Stocks

REVB earnings dates

Next earnings date
Nov 5, 2026

Revelation Biosciences Earnings Reports & History FAQ

What were Revelation Biosciences's earnings last quarter?

On REVB's earnings call on Aug 6, 2026, Revelation Biosciences (NASDAQ: REVB) reported Q2 2026 earnings per share (EPS) of -$0.87, up 96.9% year over year. Total REVB earnings for the quarter were -$3.32 million. In the same quarter last year, Revelation Biosciences's earnings per share (EPS) was -$28.04.

If you're new to stock investing, here's how to buy Revelation Biosciences stock.

When does Revelation Biosciences report earnings?

The next REVB earnings date is Nov 5, 2026. Add REVB to your watchlist to be reminded of Revelation Biosciences's next earnings date.

Is Revelation Biosciences profitable or losing money?

As of the last Revelation Biosciences earnings report, Revelation Biosciences is currently losing money. Revelation Biosciences's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$10.75 million, a 27.03% increase year over year.

What was REVB's earnings growth in the past year?

As of Revelation Biosciences's earnings date in Aug 6, 2026, Revelation Biosciences's earnings has grown -97.08% year over year. This is 114.57 percentage points lower than the US Biotechnology industry earnings growth rate of 17.49%. REVB earnings in the past year totalled -$19.20 million.

What are Revelation Biosciences's earnings expectations?

The current EPS estimate for Revelation Biosciences's earnings report in Nov 5, 2026 is -$0.88.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.